NO20091490L - Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer - Google Patents

Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer

Info

Publication number: NO20091490L
Authority: NO; Norway
Prior art keywords: leukemia; tyrosine kinase; abl tyrosine; cmin; bcr
Prior art date: 2006-09-22

Application number

NO20091490A

Other languages

English (en)

Norwegian (no)

Inventor

Insa Gathmann

Francois-Xavier Mahon

Mathieu Molimard

Stephane Picard

Yanfeng Wang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-22

Filing date

2009-04-16

Publication date

2009-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091490(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-16 Application filed by Novartis Ag filed Critical Novartis Ag

2009-06-15 Publication of NO20091490L publication Critical patent/NO20091490L/no

Links

208000032839 leukemia Diseases 0.000 title abstract 4
229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
229960002411 imatinib Drugs 0.000 abstract 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
210000004214 philadelphia chromosome Anatomy 0.000 abstract 1
230000036470 plasma concentration Effects 0.000 abstract 1
230000035945 sensitivity Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Ecology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20091490A 2006-09-22 2009-04-16 Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer NO20091490L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US82662206P	2006-09-22	2006-09-22
US82827806P	2006-10-05	2006-10-05
PCT/US2007/078978 WO2008036792A2 (en)	2006-09-22	2007-09-20	Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors

Publications (1)

Publication Number	Publication Date
NO20091490L true NO20091490L (no)	2009-06-15

Family

ID=39092883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091490A NO20091490L (no)	2006-09-22	2009-04-16	Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer

Country Status (24)

Country	Link
US (2)	US20090281113A1 (de)
EP (2)	EP2251042A3 (de)
JP (1)	JP5735742B2 (de)
KR (1)	KR20090065512A (de)
AT (1)	ATE495761T1 (de)
AU (1)	AU2007299764B2 (de)
BR (1)	BRPI0717099A2 (de)
CA (1)	CA2662977A1 (de)
CL (1)	CL2007002725A1 (de)
CY (1)	CY1111356T1 (de)
DE (1)	DE602007012122D1 (de)
DK (1)	DK2068938T3 (de)
HR (1)	HRP20110250T1 (de)
IL (1)	IL197296A (de)
MA (1)	MA30786B1 (de)
MX (1)	MX2009003082A (de)
NO (1)	NO20091490L (de)
NZ (1)	NZ575113A (de)
PL (1)	PL2068938T3 (de)
PT (1)	PT2068938E (de)
TN (1)	TN2009000094A1 (de)
TW (1)	TWI398251B (de)
WO (1)	WO2008036792A2 (de)
ZA (1)	ZA200901220B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2237783T3 (pl) *	2008-01-23	2015-04-30	Novartis Ag	Sposób optymalizacji leczenia chorób proliferacyjnych, w których pośredniczy receptor kinazy tyrozynowej kit, z użyciem imatynibu
US8697702B2 (en)	2008-12-01	2014-04-15	Novartis Ag	Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
US20110046919A1 (en)	2009-03-02	2011-02-24	Juliesta Elaine Sylvester	Method for accurate measurement of enzyme activities
FR2943418A1 (fr) *	2009-03-17	2010-09-24	Centre Nat Rech Scient	Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
US20160289663A1 (en) *	2013-11-22	2016-10-06	National Center For Child Health And Development	Novel chimeric gene atf7ip-pdgfrb of acute lymphoblastic leukemia
DK3319987T3 (da) *	2015-07-07	2021-06-21	Codexis Inc	Nye p450-bm3-varianter med forbedret aktivitet
IT201900008808A1 (it)	2019-06-13	2020-12-13	Univ Ca Foscari	Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) *	2022-06-28	2022-09-02	北京赛诺浦生物技术有限公司	一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521184A (en) *	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1169038B9 (de)	1999-04-15	2013-07-10	Bristol-Myers Squibb Company	Cyclische protein-tyrosinkinasehemmer
GB0202873D0 (en)	2002-02-07	2002-03-27	Novartis Ag	Organic compounds
US20050164196A1 (en) *	2002-04-17	2005-07-28	Dressman Marlene M.	Methods to predict patient responsiveness to tyrosine kinase inhibitors
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en)	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
AU2005254982B2 (en)	2004-06-10	2008-11-27	Irm Llc	Compounds and compositions as protein kinase inhibitors
GB0421525D0 (en)	2004-09-28	2004-10-27	Novartis Ag	Inhibitors of protein kineses
MY148074A (en)	2005-05-10	2013-02-28	Novartis Ag	Pharmaceutical compositions comprising imatinib and a release retardant

2007
- 2007-09-20 PL PL07842842T patent/PL2068938T3/pl unknown
- 2007-09-20 CA CA002662977A patent/CA2662977A1/en not_active Abandoned
- 2007-09-20 PT PT07842842T patent/PT2068938E/pt unknown
- 2007-09-20 US US12/442,126 patent/US20090281113A1/en not_active Abandoned
- 2007-09-20 JP JP2009529384A patent/JP5735742B2/ja not_active Expired - Fee Related
- 2007-09-20 AU AU2007299764A patent/AU2007299764B2/en not_active Ceased
- 2007-09-20 DK DK07842842.2T patent/DK2068938T3/da active
- 2007-09-20 HR HR20110250T patent/HRP20110250T1/hr unknown
- 2007-09-20 KR KR1020097005757A patent/KR20090065512A/ko not_active Ceased
- 2007-09-20 BR BRPI0717099-8A patent/BRPI0717099A2/pt not_active IP Right Cessation
- 2007-09-20 DE DE602007012122T patent/DE602007012122D1/de active Active
- 2007-09-20 EP EP10171365A patent/EP2251042A3/de not_active Withdrawn
- 2007-09-20 EP EP07842842A patent/EP2068938B1/de not_active Not-in-force
- 2007-09-20 MX MX2009003082A patent/MX2009003082A/es active IP Right Grant
- 2007-09-20 AT AT07842842T patent/ATE495761T1/de active
- 2007-09-20 NZ NZ575113A patent/NZ575113A/en not_active IP Right Cessation
- 2007-09-20 WO PCT/US2007/078978 patent/WO2008036792A2/en not_active Ceased
- 2007-09-21 CL CL200702725A patent/CL2007002725A1/es unknown
- 2007-09-21 TW TW096135633A patent/TWI398251B/zh not_active IP Right Cessation
2009
- 2009-02-20 ZA ZA2009/01220A patent/ZA200901220B/en unknown
- 2009-02-26 IL IL197296A patent/IL197296A/en not_active IP Right Cessation
- 2009-03-19 TN TN2009000094A patent/TN2009000094A1/fr unknown
- 2009-04-10 MA MA31775A patent/MA30786B1/fr unknown
- 2009-04-16 NO NO20091490A patent/NO20091490L/no not_active Application Discontinuation
2011
- 2011-03-23 CY CY20111100319T patent/CY1111356T1/el unknown
2016
- 2016-09-22 US US15/272,576 patent/US20170007605A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20090065512A (ko)	2009-06-22
TN2009000094A1 (en)	2010-08-19
WO2008036792A3 (en)	2008-11-13
IL197296A (en)	2011-11-30
EP2068938A2 (de)	2009-06-17
JP2010504353A (ja)	2010-02-12
CA2662977A1 (en)	2008-03-27
HK1133194A1 (en)	2010-03-19
TW200822926A (en)	2008-06-01
EP2251042A3 (de)	2012-05-02
WO2008036792A2 (en)	2008-03-27
ATE495761T1 (de)	2011-02-15
CY1111356T1 (el)	2015-08-05
EP2068938B1 (de)	2011-01-19
DK2068938T3 (da)	2011-04-04
US20090281113A1 (en)	2009-11-12
PT2068938E (pt)	2011-03-23
JP5735742B2 (ja)	2015-06-17
BRPI0717099A2 (pt)	2013-10-15
US20170007605A1 (en)	2017-01-12
CL2007002725A1 (es)	2008-05-16
DE602007012122D1 (de)	2011-03-03
IL197296A0 (en)	2011-08-01
PL2068938T3 (pl)	2011-06-30
ZA200901220B (en)	2010-02-24
MX2009003082A (es)	2009-04-01
EP2251042A2 (de)	2010-11-17
NZ575113A (en)	2012-03-30
AU2007299764A1 (en)	2008-03-27
MA30786B1 (fr)	2009-10-01
TWI398251B (zh)	2013-06-11
HRP20110250T1 (hr)	2011-05-31
RU2009114856A (ru)	2010-10-27
AU2007299764B2 (en)	2011-10-13

Similar Documents

Publication	Publication Date	Title
NO20091490L (no)	2009-06-15	Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer
Cappuzzo et al.	2003	Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
EA201190042A1 (ru)	2012-02-28	Имидазопиразиновые ингибиторы тирозинкиназы syk
BRPI0508286A (pt)	2007-07-31	métodos para determinar a possibilidade de efetividade de um tratamento seletivo de receptor de fator de crescimento epidérmico em um paciente, para tratar um paciente e para selecionar um composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, sonda, kit, composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, composição farmacêutica, ácido nucléico e proteìna isolada
DK2413142T3 (da)	2013-07-22	Fremgangsmåde til forudsigelse af NSCLC-patienters reaktion på behandling med en EGFR-TK-inhibitor
KR20210137045A (ko)	2021-11-17	수면 개선 방법
EP1720574A4 (de)	2009-09-09	Verfahren zur behandlung von abnormalem zellwachstum mit c-met und tor-hemmern
EA201071422A1 (ru)	2011-08-30	Способы лечения заболеваний, связанных с мейотическим кинезином
WO2010066891A3 (en)	2010-08-26	Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients
DE602005008639D1 (de)	2008-09-11	Behandlung von entzündungen
DK2196199T3 (da)	2014-11-03	Behandling af fantomfænomener
EA201300410A1 (ru)	2014-01-30	Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2
RU2017143182A (ru)	2019-06-13	Способы и композиции для ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы
Wajid et al.	2018	Early molecular response with imatinib therapy in chronic myeloid leukemia and its association with baseline white blood cell count and spleen size
BRPI0418022A (pt)	2007-04-17	biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor
US20110224224A1 (en)	2011-09-15	Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate
DE602004016547D1 (de)	2008-10-23	1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
TW200507828A (en)	2005-03-01	Method for treatment of chemotherapy-induced diarrhea
Büchner et al.	2004	Two years of experience using stimulation rates between 800 and 5000 pps with the clarion CII implant
RU2483732C2 (ru)	2013-06-10	СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ
Radich	2023	The (near) miracle of therapy in chronic myeloid leukaemia.
CN102526734A (zh)	2012-07-04	治疗年龄相关性听力损失的药物组合物及其应用
WO2001045690A3 (en)	2002-07-25	Use of bvdu for inhibiting the growth of hyperproliferative cells
ATE312612T1 (de)	2005-12-15	Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen
Snead et al.	2008	New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?

Legal Events

Date	Code	Title	Description
2015-04-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application